Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.

CDK9 is an essential drug target correlated to the development of acute myeloid leukemia (AML). Starting from the hit compound 10, which was discovered through a screening of our in-house compound library, the structural modifications were carried out based on the bioisosterism and scaffold hopping strategies. Consequently, compound 37 displayed the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM, which was nearly 1500-fold higher than compound 10. In addition, compound 37 exhibited significant antiproliferative activity in broad cancer cell lines. Further investigation of in vivo properties demonstrated that compound 37 could be orally administrated with an acceptable bioavailability (F = 33.7%). In MV-4-11 subcutaneous xenograft mouse model, compound 37 (7.5 mg/kg) could significantly suppress the tumor progression with a T/C value of 27.80%. Compound 37 represents a promising lead compound for the development of a novel class of CDK9 inhibitors for the treatment of acute myeloid leukemia.

[1]  A. Ferguson,et al.  Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. , 2020, Journal of medicinal chemistry.

[2]  Zhiyu Li,et al.  Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. , 2020, Journal of medicinal chemistry.

[3]  A. Mai,et al.  CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas , 2020, Frontiers in Pharmacology.

[4]  M. Juhás,et al.  Molecular Interactions of Pyrazine-based Compounds to Proteins. , 2020, Journal of medicinal chemistry.

[5]  Qian Ye,et al.  Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma , 2019, Molecular Cancer.

[6]  C. Zahnow,et al.  Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer , 2018, Cell.

[7]  A. Giordano,et al.  CDK9 inhibitors in acute myeloid leukemia , 2018, Journal of experimental & clinical cancer research : CR.

[8]  A. Giordano,et al.  CDK9: A key player in cancer and other diseases , 2018, Journal of cellular biochemistry.

[9]  R. Young,et al.  Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. , 2017, Nature chemical biology.

[10]  H. Briem,et al.  Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer , 2017, ChemMedChem.

[11]  Hong Liu,et al.  Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. , 2017, Journal of medicinal chemistry.

[12]  A. Rice,et al.  Cyclin-dependent kinases as therapeutic targets for HIV-1 infection , 2016, Expert opinion on therapeutic targets.

[13]  Sandeep Rana,et al.  Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy , 2016, Journal of medicinal chemistry.

[14]  P. Lienau,et al.  Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. , 2016, ACS chemical biology.

[15]  J. Nemunaitis,et al.  A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies , 2013, Journal of Translational Medicine.

[16]  P. Kaldis,et al.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation , 2013, Development.

[17]  M. Noble,et al.  Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities , 2013, Journal of Medicinal Chemistry.

[18]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[19]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[20]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[21]  L. Kèlland,et al.  Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status , 2000, Expert opinion on investigational drugs.

[22]  D. Johnson,et al.  Cyclins and cell cycle checkpoints. , 1999, Annual review of pharmacology and toxicology.